Washington University School of Medicine

Digital Commons@Becker
Open Access Publications
2012

Heart rate variability changes at 2400 m altitude predicts acute
mountain sickness on further ascent at 3000–4300 m altitudes
Heikki M. Karinen
University of Tampere

Arja Uusitalo
University of Helsinki

Henri Vaha-Ypya
University of Jyvaskyla

Mika Kahonen
University of Tampere

Juha E. Peltonen
University of Helsinki

See next page for additional authors

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Recommended Citation
Karinen, Heikki M.; Uusitalo, Arja; Vaha-Ypya, Henri; Kahonen, Mika; Peltonen, Juha E.; Stein, Phyllis K.; Viik,
Jari; and Tikkanen, Heikki O., ,"Heart rate variability changes at 2400 m altitude predicts acute mountain
sickness on further ascent at 3000–4300 m altitudes." Frontiers in Physiology. 3,. 336. (2012).
https://digitalcommons.wustl.edu/open_access_pubs/2242

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been
accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker.
For more information, please contact vanam@wustl.edu.

Authors
Heikki M. Karinen, Arja Uusitalo, Henri Vaha-Ypya, Mika Kahonen, Juha E. Peltonen, Phyllis K. Stein, Jari
Viik, and Heikki O. Tikkanen

This open access publication is available at Digital Commons@Becker: https://digitalcommons.wustl.edu/
open_access_pubs/2242

ORIGINAL RESEARCH ARTICLE
published: 30 August 2012
doi: 10.3389/fphys.2012.00336

Heart rate variability changes at 2400 m altitude predicts
acute mountain sickness on further ascent at
3000–4300 m altitudes
Heikki M. Karinen 1,2*, Arja Uusitalo 2 , Henri Vähä-Ypyä 3 , Mika Kähönen 4 , Juha E. Peltonen 2,7 ,
Phyllis K. Stein 5 , Jari Viik 6 and Heikki O. Tikkanen 2,7
1
2
3
4
5
6
7

Unit for Occupational Health, Department of Health Sciences, University of Tampere, Tampere, Finland
Department of Sports and Exercise Medicine, Institute of Clinical Medicine, University of Helsinki, Helsinki, Finland
Department of Biology of Physical Activity, University of Jyväskylä, Jyväskylä, Finland
Department of Clinical Physiology, University of Tampere and Tampere University Hospital, Tampere, Finland
Division of Cardiology, Washington University School of Medicine, St. Louis, MO, USA
Department of Biomedical Engineering, Tampere University of Technology, Tampere, Finland
Clinic for Sports and Exercise Medicine, Foundation for Sports and Exercise Medicine, Helsinki, Finland

Edited by:
Federico Lombardi, University of
Milan, Italy
Reviewed by:
Federico Lombardi, University of
Milan, Italy
Robert Boushel, University of
Copenhagen, Denmark
*Correspondence:
Heikki M. Karinen, Department of
Health Sciences, University of
Tampere, Medisiinarinkatu 3,
33521 Tampere, Finland.
e-mail: heikki.karinen@uta.fi

Objective: If the body fails to acclimatize at high altitude, acute mountain sickness
(AMS) may result. For the early detection of AMS, changes in cardiac autonomic function
measured by heart rate variability (HRV) may be more sensitive than clinical symptoms
alone. The purpose of this study was to ascertain if the changes in HRV during ascent are
related to AMS. Methods: We followed Lake Louise Score (LLS), arterial oxygen saturation
at rest (R-SpO2 ) and exercise (Ex-SpO2 ) and HRV parameters daily in 36 different healthy
climbers ascending from 2400 m to 6300 m altitudes during five different expeditions.
Results: After an ascent to 2400 m, root mean square successive differences, highfrequency power (HF2 min ) of HRV were 17–51% and Ex-SpO2 was 3% lower in those
climbers who suffered from AMS at 3000 to 4300 m than in those only developing AMS
later (≥5000 m) or not at all (all p < 0.01). At the altitude of 2400 m RMSSD2 min ≤ 30 ms
and Ex-SpO2 ≤ 91% both had 92% sensitivity for AMS if ascent continued without extra
acclimatization days. Conclusions: Changes in supine HRV parameters at 2400 m were
related to AMS at 3000–4300 m Thus, analyses of HRV could offer potential markers for
identifying the climbers at risk for AMS.
Keywords: extreme altitude, altitude illness, heart rate variation, mountaineering

INTRODUCTION
When ascending to high altitude, the body needs to acclimatize to low atmospheric pressure and hypoxic hypoxia (Hackett
and Roach, 2001). If the adaptation process fails due to too
rapid ascent rate or susceptibility of the climber, one or more
of three illnesses may result: acute mountain sickness (AMS),
high altitude cerebral edema (HACE) or high altitude pulmonary
edema (HAPE). AMS is the most common of these problems
affecting 25% of those who ascend to altitudes of 1850–2750 m
(Honigman et al., 1993), 42% at altitudes of 3000 m (Hackett
and Roach, 2001) and as many as 75% among those attempting Mount Kilimanjaro (5984 m) (Karinen et al., 2008). AMS is a
non-specific syndrome characterized by the presence of headache
and at least one of the following: gastrointestinal symptoms
(loss of appetite, nausea, and vomiting), insomnia, dizziness, and
weakness or fatigue. It is a self-limiting syndrome, which usually resolves in 1–2 days if properly treated (rest, descent to lower
altitude, medication etc.) but may sometimes progress to more
serious altitude illnesses such as HAPE and HACE (Hackett and
Roach, 2001; Imray et al., 2011).
The exact mechanism causing AMS is unknown, but a marked
increase in peripheral sympathetic activity is a common feature
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of AMS (Kamimori et al., 2009) and may be involved in the
pathogenesis of HAPE (Mazzeo et al., 1998; Duplain et al., 1999;
West, 2004). Heart rate variability (HRV) reflects sympathetic and
parasympathetic cardiac autonomic nervous system regulation.
Several studies have shown a transient reduction in parasympathetic and increased sympathetic activity during acute exposure
to hypobaric hypoxia (Zuzewicz et al., 1999; Sevre et al., 2001;
Saito et al., 2005; Hainsworth et al., 2007) which tended to be
reversed with acclimatization (Cornolo et al., 2004).
There is a need for a non-invasive, specific and convenient
method under field conditions for the detection of inadequate
acclimatization and impending AMS. The arterial oxygen saturation (SpO2 ) measurement is useful in anticipating AMS (Roach
et al., 1998; Karinen et al., 2010) but use of pulse oximetry under
field conditions is susceptible to many disruptive factors e.g.,
temperature (Luks and Swenson, 2011). Reduction in parasympathetic and increased sympathetic activity during acclimatization
and AMS at 3180–4559 m altitudes have been shown in several
studies (Loeppky et al., 2003; Lanfranchi et al., 2005; Chen et al.,
2008; Huang et al., 2010). To the best of our knowledge, studies
on HRV conducted in the field at extreme altitudes (>5000 m) are
still lacking, despite two studies at simulated altitude (Yamamoto
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The study group consisted of participants in four different expeditions to Denali (Denali 1, Denali 2), Shisha Pangma and Mount
Everest. All subjects were informed about the objective of the
study and the experimental protocol. The Ethics Committee of
Tampere University Hospital, Finland, approved the study protocol, and all subjects gave informed consent prior to the measurements, as stipulated in the Declaration of Helsinki. Thirty six
different healthy volunteers (2 women and 34 men) with an age
range of 24–45 years participated in this study. Subjects’ mean
age was 32 (SD 6) years, body mass index (BMI) 25 (3) kg/m2
and maximal oxygen uptake (V̇O2max ) 59 (7) ml/kg/min. None
of the subjects had been exposed to an altitude above 1000 m
within the 6 months prior to this study. They were all lowland
dwellers and recreational mountaineers, and during the expeditions none had taken acetazolamide as an AMS prophylaxis. Two
climbers were taking regular medication for asthma but no one
was using oral steroids, salmeterol, sildenafil or nifedipin. All
expeditions were organized in April-May. Ascent profiles were
similar at sleeping altitudes, but three expeditions had faster
and two slower ascent rate. Before the expeditions, all members
underwent a medical examination including resting ECG and
flow volume spirometry. To examine their exercise responses and
to measure maximal oxygen uptake (V̇O2max ), they performed an
incremental clinical exercise test on a cycle ergometer (Ergoline
800S, Ergoline GmbH, Bitz, Germany). They started cycling at
20 W and work rate was increased stepwise 20 W/min up to volitional fatigue. A 12-lead ECG was obtained at rest before the
exercise, and during the exercise test. All subjects had a normal EKG and none developed arrhythmias during the exercise
test.

morning after 7–8 h night rest at that altitude by heart rate monitors (Suunto T6, Suunto, Vantaa, Finland or S810, Polar Electro,
Kempele, Finland). HR recordings were made in the supine position, after at least 15 min of rest in the same position while each
subject laid quietly and breathed spontaneously. Then subjects
started their HR monitors and continued lying down for 3 min.
The last 2 min were chosen for data analysis. According to the
Task Force of the European Society of Cardiology and the North
American Society of Pacing and Electrophysiology (Task Force,
1996), the preferred duration of ECG recordings for computing short-term HRV components is 5 min. The recording should
last at least 10 times the wavelength of the lowest frequency
bound of the investigated component (Task Force, 1996). Thus a
recording of approximately 1 min is needed to assess the HF and
approximately 2 min are needed to address the LF component. In
our study the duration of stationary RRI time series was 2 min,
which should be adequate for the determination of the HRV
components evaluated (Koskinen et al., 2009). The arterial oxygen saturation at rest (R-SpO2 ) was measured by finger oximetry
(Nonin Medical, Onyx 9500, Plymouth MN, USA) after 15 min
rest while the subject was seated for an additional 2 min. During
this period, R-SpO2 was observed four times at 15 s intervals and
the average R-SpO2 of these was recorded for data analysis. The
arterial oxygen saturation during exercise (Ex-SpO2 ) at altitude
was measured with a standard walking test (Karinen et al., 2010).
The climber walked and controlled his speed with the HR monitor so that HR was approximately 150 beats/min during 3–5 min
walking. Temperature varied between +20 and −15◦ C and hands
were covered by mittens during walking, which ended inside a
tent. The inside temperature was mostly between +5 and 20◦ C
because of extensive solar radiation or a stove. Immediately after
the cessation of walking, SpO2 was measured in sitting position
by finger oximetry four times at 5 s intervals during the first 15 s
of recovery starting immediately after stopping the exercise test.
The average of these values was recorded as Ex-SpO2 for data
analysis. We observed that SpO2 decreased 15 s after the exercise
began. During the first 15 s the SpO2 values remained very steady,
varying just 0–1% unit, thus quite accurately reflecting also SpO2
during exercise.

DATA COLLECTION DURING ASCENT

DATA ANALYSIS

Autonomic cardiac function was assessed by analysis of R-R
intervals (RRI). In power spectral analysis of HRV total variability of RRI is divided into low and high frequency bands.
High frequency power (HF power, 0.15–0.40 Hz) reflects cardiac
parasympathetic modulation and is influenced by respiration.
Low frequency power (LF power, 0.04–0.15 Hz) reflects both cardiac sympathetic and parasympathetic modulation. The ratio of
LF and HF powers (LF/HF) has been reported to reflect sympathovagal balance. RMSSD is the square root of the mean squared
differences of successive RRI and it is considered to be an index of
cardiac parasympathetic modulation (Task Force, 1996).
In the present study, HRV and SpO2 data were collected every
day during ascent at altitudes of 2400, 3000, 3500, 4300, 5000, and
5300 m in all expeditions, and up to 5600 and 6300 m at Shisha
Pangma. Data collection was continued until the base camp
of each mountain was reached. Measurements were done every

Data processing and analysis were performed after the expeditions
by Polar Precision Performance software (version 3.02.007) and
Kubios software (version 2.0) (Niskanen et al., 2004). Areas of
ectopy or artifact were identified and fixed by manual or automatic error correction. Corrected segments were less than 5% of
the analyzed data. Analysis of HRV was done for stationary 2 min
data segments. The power spectra were quantified by measuring
the area in two frequency bands. The HF2 min power was calculated for frequency band 0.15–0.40 Hz and LF2 min power for
frequency band 0.04–0.15 Hz.
After the HRV and SpO2 measurements subjects were scored
according to the Lake Louise scoring (LLS) AMS system, which
include a self-report questionnaire related to the presence and
severity of symptoms and a clinical assessment (Hackett and Oelz,
1992). The LLS was obtained by adding the score of the clinical section to the self-report questionnaire. AMS was diagnosed

et al., 1993; Wille et al., 2004). Therefore the purpose of this
study was to evaluate whether HRV is related to AMS during
ascent and provides new information on the changes in cardiac
autonomic function as measured by HRV and not limited to altitudes between 2400 and 5000 m, which are most frequent among
climbers, but also at extreme altitudes above 5000 m under field
conditions.

MATERIALS AND METHODS
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FIGURE 1 | Ascent profiles of different expeditions and number of AMS
cases at different altitudes. Three climbers descended after 4300 m
because of AMS. Measurements were made daily up to 5300 m except on

according to a recent gain in altitude, the presence of headaches
and at least one of the following symptoms: gastrointestinal
(GI) upset, fatigue, dizziness or insomnia. To study, retrospectively, whether HRV changes could have predicted AMS at higher
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Shisha Pangma, where measurements were made up to 5600 m. AMS,
Acute Mountain Sickness; AMS∗ , AMS at this altitude; AMS∗∗ , AMS at some
other altitude.

altitudes, we divided the study group into two groups: (1) If the
LLS was ≥ 3 at any altitude the subject was assigned to the AMS
group, and (2) If the LLS was ≤ 2 at every altitude measured, the
subject was assigned to the no-AMS group.
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STATISTICAL ANALYSIS

Table 2 | Resting heart rate (HR) and HRV parameters at 2400 m

Continuous values are presented as means ± standard deviation
(SD). The frequency of parameters was assessed by x2 tests with
Yates’ correction. Differences between AMS and no-AMS groups
were compared by nonparametric t-test. Correlations between
the LLS and clinical and autonomic variables were assessed
by Pearson’s correlation. In all tests p ≤ 0.05 was considered
significant.

among the climbers who subsequently developed AMS at two
different altitude ranges, and those who had no subsequent AMS.
no-AMS

AMS at

AMS at ≥ 5000 m

(n = 12)

3000–4300 m

(n = 12)

(n = 12)
HR (beats/min)

70 ± 9

82 ± 15*

62 ± 8*†

RMSSD (ms)

43 ± 25

21 ± 13*

48 ± 32†

RESULTS

lnLF

(ms2 )

7±1

6 ± 1‡

6±1

In total, 36 subjects were studied up to the altitude of 4300 m.
Three discontinued because of AMS and the remaining 33 continued up to 5000 and 5300 m altitudes. Five made all measurements
at 5600 and one at 6300 m altitude. The Denali 1 and Shisha expeditions reached the altitude of 5000 m in 7 days (n = 16) and
the Denali 2 and Everest expeditions took 11–17 days to reach
the same altitude (n = 20) (Figure 1). Acute mountain sickness
developed in 24 out of 36 (66%) subjects at some altitude between
3000 and 5600 m, including both women and 22 of 34 men, while
12 men (34%) did not get AMS at any altitude (no-AMS group).
There were 11 AMS cases in the faster group and 13 AMS cases
in the slower group. The groups did not differ in age, BMI or
V̇O2max . The descriptive data of participants and ascents for each
expedition are presented in Table 1 and Figure 1.
During this study, the daily ascent rates were mostly higher
than what is generally recommended (300 m/day) but quite common for these mountains (range 400–1500 m). In the no-AMS
group, RMSSD2 min , LF2 min and HF2 min increased in the first few
days of the ascent. Above 3500 m all HRV parameters decreased
while HR increased.
The number of AMS cases at different altitudes is presented in
Figure 1. Among those who suffered from AMS, LLS scores varied
between 3 and 8. Most of the AMS cases occurred at 5300 m (n =
10), and the prevalence of AMS increased significantly with altitude and fast ascent rate on the day before onset (both p < 0.001)
(Figure 1). Headache and difficulty in sleeping were the most frequent symptoms of AMS followed by GI symptoms, fatigue, and
dizziness.
At 2400 m altitude, RMSSD2 min and HF2 min were lower
among those climbers who got AMS at lower altitudes
(3000–4300 m) (n = 12) than in those who got AMS 3–7
days later at higher altitude (≥5000 m) (n = 12) or not at
all (n = 12) (Table 2). HR2 min , lnHF2 min and RMSSD2 min at

lnHF (ms2 )

6±1

5 ± 2*

7 ± 2†

LF/HF

5±4

6±6

1.2 ± 1.1‡†

R-SpO2

94 ± 1

93 ± 2

94 ± 2

Ex-SpO2

91 ± 2

88 ± 3‡

89 ± 3*

Table 1 | Demographic data (age, BMI, and V̇O2max ) of the study
population.
Characteristic

no-AMS

AMS at some altitude

All

(n = 12)

(n = 24)

(n = 36)

Age (years)∗

30 ± 5

33 ± 7

32 ± 6

BMI (kg/m2 )

24 ± 1

25 ± 4

25 ± 3

V̇O2max (ml/kg/min)

60 ± 4

60 ± 9

59 ± 7

There were no statistically significant differences in the basic characteristics
between no-AMS and AMS groups.
Values are mean ± SD. BMI, body mass index; V̇O2max , maximal oxygen uptake.
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Values are presented in mean ± SD. (∗ p < 0.05, ‡p < 0.01, difference between
AMS 3500–4300 m vs. no-AMS groups and AMS ≥ 5000 m vs. no-AMS groups,
†p < 0.05, difference between AMS 3500–4300 m vs. AMS ≥ 5000 m).

2400 m correlated with the lowest altitude at which a climber suffered AMS (AMS altitude) (Figure 2). There were no differences
between R-SpO2 at 2400 m and later onset of AMS, but Ex-SpO2
was statistically higher in the no-AMS than the AMS group at
3000–4300 m (p < 0.01) (95% CI 3 (1–5) and in the AMS at ≥
5000 m group (p < 0.05). However, Ex-SpO2 did not correlate
with the AMS altitude (r = −0.028). At the altitude of 2400 m
RMSSD2 min ≤ 30 ms and Ex-SpO2 ≤ 91% both had 92% sensitivity for AMS at 3000–4300 m if the ascent continued without
extra acclimatization days (Figure 3). The sensitivity, specificity,
positive, and negative predicative values for chosen cut-off values
are presented in Table 3.

DISCUSSION
Our most important finding was that subjects susceptible to AMS
had lower HRV before the clinical manifestations of AMS than
those who acclimatized well and did not get AMS. This is a new
finding and offers fascinating options for predicting AMS at high
altitude in field conditions.
The diagnosis of AMS is clinical, but some specific changes in
cardiac autonomic function measured by HRV have been estimated to be more sensitive in the detection of the early signs
of AMS than clinical symptoms alone at high altitudes (Saito
et al., 2005). HRV is reported to decrease in absolute units
(Hughson et al., 1994; Bernardi et al., 1998; Kanai et al., 2001)
and LF/HF mostly increased when subject got AMS (Loeppky
et al., 2003; Lanfranchi et al., 2005; Chen et al., 2008; Huang
et al., 2010). There are, however, also opposite findings reported
about HRV (Koehle et al., 2010). However, studies conducted
in the field at high and extreme altitudes (>5000 m) are still
lacking.
During mild sympathetic activation, the observed increase in
HR has been reported to be associated with an increase in LF
power (Elghozi and Julien, 2007). However, with more intense
sympathetic stimulation, the increase in HR was reported to
be associated with an overall decrease in HRV, including its LF
component. Our present findings on changes in HRV values at
extremely high altitudes support this concept.

August 2012 | Volume 3 | Article 336 | 4

Karinen et al.

FIGURE 2 | Negative correlation between HR and positive correlation
between lnHF, lnLF, and RMSSD at 2400 m altitude and the
lowest altitude at which a climber got AMS (HR r = −0.743, p < 0.01;

Changes in HRV and AMS

lnHF r = 0.558, p < 0.05, lnLF r = 0.302, p > 0.05, RMSSD
r = 0.495, p < 0.05). no-AMS subjects datapoints are added at 5600 m
level.

FIGURE 3 | Scattergram showing the distribution of values of RMSSD and Ex-SpO2 measured in 24 study subjects at 2400 m in AMS and no-AMS.
The cut-off lines RMSSD2min ≤ 30 ms and Ex-SpO2 ≤ 91% are for 92% sensitivity for AMS.

At 2400 m the no-AMS group had higher HRV and lower
HR2 min than the AMS group. The differences are not related
to differences in physical fitness in the AMS and no-AMS
groups because the basic maximum oxygen uptake did not differ

www.frontiersin.org

significantly between the groups (59 ± 11 vs. 60 ± 4, p > 0.05).
Furthermore, clear changes did not come in connection with
the ascent. However, in the no-AMS group HF2 min tended to be
lower, while LF2 min tended to be higher than in the AMS group.
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Table 3 | Sensitivity and specificity of chosen parameters at 2400 m altitude for AMS at 3000–4300 m.
Sensitivity (%)

Specificity (%)

Positive predicative value (%)

Negative predicative value (%)

95% confidence interval

RMSSD2 min ≤ 30

92

58

61

83

22 (5–39)

Ex-SpO2 ≤ 91 %

92

40

65

80

3 (1–5)

The physiologic significance of these findings remains uncertain, but they do not directly support the earlier assumption that
AMS is simply connected with higher cardiac sympathetic activity. Rather, it seemed that a rise in cardiac sympathetic activity
would have been a protective phenomenon against altitude illness. However, altitude illness is a dynamic process. It may be that
as the AMS proceeds, HRV could further decrease. In other words,
changes in HRV were related to higher altitudes in all climbers,
but also notably to acclimatization and especially to failure to
acclimatize.
The present findings are still generally in agreement with
those of earlier studies and provide further insights into the
usefulness of HRV in the prediction of AMS under field conditions. Several studies have shown that of SpO2 measurements at rest (R-SpO2 ) and immediately after exercise (Ex-SpO2 )
are predictors of AMS (Roach et al., 1998; Saito et al., 2005;
Burtscher et al., 2008; Karinen et al., 2010). Our study supports this. At 2400 m altitude the Ex-SpO2 was statistically higher
in no-AMS group than AMS 3000–4300 group (p < 0.01) and
AMS ≥ 5000 m group (p < 0.05). However, the SpO2 measurements made by pulse oximetry under field conditions may
be susceptible to many disruptive factors (temperature, bright
light, cold fingers etc.) (Luks and Swenson, 2011). Therefore, it
is desirable to have an another parameter(s) to follow-up for
AMS susceptibility. Our findings support the possibility that
HRV could be used along with commonly measured physiological parameters, HR and SpO2 , clinical status and Lake Louise
questionnaire for AMS prediction in the short time period at
moderate altitudes. The altitude of 5000 m was reached mainly
1–2 weeks after the measurements at 2400 m and the ascent
rates per day were high just before reaching this altitude (700–
1500 m/day). This may explain better the high prevalence of AMS
at 5000–5300 m than a predominant vagal modulation at rest at
2400 m.
The limitations of the present study include the relatively small
study group (n = 33) at extreme altitude (>5000 m). The correlations between HRV parameters and AMS are rather weak. Thus,
further studies with larger populations are needed to verify the
early changes in HRV between subjects with and without AMS
and/or other high-altitude illnesses, especially at extreme altitudes, where the consequences of AMS, HACE, and HAPE may
dramatic. The length of measurements at high altitude may have
been too short to fully observe trends of changes in HRV variables between subjects with and without AMS or to capture other
HRV measures that could reflect more severe periodic breathing. The differences in ascent rates, the places studied and the
altitudes studied may in part explain the differences between the
different results. Environmental and/or cardiovascular effects of
previous exercise may have been factors in the autonomic patterns
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observed in subjects with AMS in our study. However, subjects
with and without AMS were studied under the same field conditions and after similar recovery times as regards ascent. The
ascent rates during the expeditions were normal and widely used
in the mountains. Therefore, exercise and environmental factors may not explain the differences in autonomic cardiovascular
function observed in association with AMS in our study. HRV
is also partially influenced by respiratory rate and depth (Task
Force, 1996; Penttilä et al., 2001). In the HRV frequency spectrum, too, power in the entire frequency area, not just the HF
band, is decreased if the respiration rate increases (Task Force,
1996). Normally respiration rates will increase somewhat at high
altitude, but we do not know if the respiration rate is higher in
subjects with AMS than in subjects with no AMS. In this study,
the subjects were breathing spontaneously and some of the subjects may have had breathing rate close to or below 0.15 Hz,
which is the lowest boundary for the HF band. For this reason,
if altitude or AMS changed respiratory HRV, it cannot be exclusively judged by changes in HF or LF/HF. Unfortunately, we do
not have sea-level HRV data for all subjects, so we cannot estimate whether those climbers whose basic level of HF is higher
could acclimatize better than those whose HF level is lower at
sea-level.
Periodic breathing has reported to exist at high altitude mainly
during the sleep, but also in some extent during wake (Insalaco
et al., 1996; Fan et al., 2012). Because the breathing frequency
was not measured in our study, we cannot exclude it totally
(McMullen et al., 2012). However, the visual analysis of RRI
tachograms, AR spectrum and Poincare plots do not support the
existence of periodic breathing during the measurements. The
measurement periods were 2 min so we can assume that any significant periodic breathing was not seen when lying down during
this measurement period.
The strengths of the present study are that the rate of ascent,
altitude of origin and time of day of testing were known. Also,
within each group every climber had a similar diet, they were relatively homogenous in their exercise capacity and they climbed
the same route on mountains over a short period of time with
essentially the same snow and weather conditions. Barometric
pressure varied from day to day but during measurements it was
stable.
In conclusion, at 2400 m decreased RMSSD2 min and HF2 min
both predicted AMS in a few days if the ascent continued
without rest days. Autonomic cardiac response to increasing altitude could be a low-cost non-invasive test to predict impending AMS and to help distinguish those who
are at risk for AMS and those who are acclimatizing well.
The trigger values typical for impending AMS await further
studies.
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